Chinese Neurosurgical Journal Report Identifies FAM111B as Key Molecular Driver of Glioma Progression
BEIJING, CHINA, May 29, 2025 / EINPresswire.com / -- Gliomas are among the deadliest brain tumors, with limited treatment options and poor survival rates. Scientists from China identified FAM111B, a DNA-repair-associated protein, as a key driver of glioma progression. The study shows that FAM111B overexpression enhances tumor growth and aggressiveness by activating the PI3K/AKT pathway. This is the first research to link FAM111B to gliomas, offering a promising new biomarker and therapeutic target for this intractable disease.
Gliomas are the most prevalent and aggressive form of primary brain tumors in adults, with dismal survival rates despite surgery, radiation, and chemotherapy. Scientists continue to search for molecular drivers that could serve as new therapeutic targets. Now, researchers led by Dr. Quan Du from Zhejiang Chinese Medical University and Westlake University in China have identified a promising candidate: a protein known as FAM111B.
'Our findings revealed that FAM111B affected glioma malignancy by modulating the PI3K/AKT pathway,' highlights lead researcher Dr. Du. 'This presents a new potential avenue for therapeutic intervention in the treatment of glioma.'
The study, published on May 19 2025, in the Chinese Neurosurgical Journal, is the first to examine the role of FAM111B in gliomas. Prior research had linked FAM111B to cell cycle regulation, DNA repair, and fibrosis-related diseases. However, its function in brain cancer was previously unknown.
Using genomic databases including The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA), the research team found that FAM111B expression is significantly elevated in glioma tissues compared to healthy brain tissue. Moreover, higher expression levels correlated with older patient age, more advanced tumor grade, and poorer clinical outcomes—including reduced overall survival and disease-free survival. The authors confirmed these findings experimentally. Glioma cell lines and tumor samples showed significantly higher levels of FAM111B protein compared to normal tissues. When FAM111B was overexpressed in glioma cells, their proliferation, invasion, and migration dramatically increased. Conversely, knocking down FAM111B suppressed these malignant traits.
Further, in vivo experiments using mice confirmed FAM111B's role in promoting tumor growth. Mice injected with glioma cells overexpressing FAM111B developed significantly larger and heavier tumors than controls.
To uncover the molecular mechanism behind these effects, the team conducted pathway enrichment analysis. Results pointed strongly to the PI3K/AKT signaling cascade—a pathway long associated with tumor growth and resistance to therapy. Further tests showed that FAM111B overexpression increased phosphorylation of PI3K and AKT, while silencing the protein had the opposite effect.
'FAM111B regulates glioma cell malignant features via the PI3K/AKT pathway,' the Dr. Du wrote. 'These results support the hypothesis that FAM111B influences the malignant features of glioma cells primarily through the PI3K/AKT pathway.'Treatment with a PI3K inhibitor reversed the aggressive behavior caused by FAM111B overexpression, strongly suggesting a direct regulatory role. This not only strengthens the case for FAM111B as a key driver of glioma but also highlights it as a promising therapeutic target. The study's strength lies in its comprehensive approach, combining bioinformatics, cell culture, animal modeling, and molecular assays. However, the authors acknowledge the study's limitations, particularly the small patient sample size and the need for broader validation across multiple research centers.
Nonetheless, the implications are significant. Identifying FAM111B as an independent prognostic marker and a key modulator of a known cancer pathway adds a valuable tool to the glioma research arsenal.
While therapies targeting the PI3K/AKT pathway already exist, this research may pave the way for more precise, FAM111B-guided interventions. 'FAM111B has emerged not only as a critical biomarker for the development of glioma,' Dr Du concludes, 'but also as a promising novel target for therapeutic intervention.'
As researchers work to solve the complex puzzle of brain cancer, FAM111B may soon take center stage.
***
Reference
Title of original paper: The role of FAM111B in the malignant progression and molecular regulation of human glioma through the PI3K/Akt pathway
Journal: Chinese Neurosurgical Journal
DOI: https://doi.org/10.1186/s41016-025-00395-6
Yi Lu
Chinese Neurosurgical Journal
+86 10 5997 8478
[email protected]
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
01-07-2025
- Associated Press
HealthBenefits.co.in Launches Global Wellness Platform with Smart Health Tracking Tools
empowers everyday users with free tracking tools, health calculators, and beginner-friendly wellness content. 'Quote: We created to turn complex wellness info into easy, actionable tools for everyday people.'— Madhusmita Sahu, Founder of HealthBenefits NEW YORK, NY, UNITED STATES, July 1, 2025 / / -- Health -conscious Americans and global users now have a smarter way to manage their wellness. a digital health platform, has officially launched to provide free health tracking tools and expert wellness content — all in one easy-to-use website. From BMI and calorie calculators to wellness blogs on nutrition, mental health, and immunity, the platform helps users take actionable steps toward a healthier lifestyle — without the need to download an app or pay for premium services. 'We created to make health support more accessible,' said the site's founder. 'Wellness isn't just for experts — it's for everyone. Our tools and articles help users make smarter choices, every day.' Originally launched in October 2023, the site is now expanding its reach to a global audience — including the United States, where interest in holistic wellness, stress management, and digital health tracking continues to grow. 🔍 Key Features for U.S. Users: Free Tools: Track BMI, calories, hydration, and more Science-Backed Wellness Content: Easy-to-read tips on fitness, nutrition, sleep, and immunity No Signup Required: Start using instantly — no login or downloads needed Optimized for Mobile: Works seamlessly on phones and tablets Weekly Updates: Fresh content added regularly Whether you're a college student looking to stay healthy, a busy parent trying to manage stress, or just someone who wants to track personal progress — offers tools designed to support everyday wellness. 📢 About is a global health and wellness website founded in India. It offers free, user-friendly digital tools and expert content to help users track health data, build better habits, and stay informed. With a growing international audience, the platform is committed to making health guidance simple and accessible for all. 🔗 Website: 🌐 📞 Media Contact: Email: [email protected] Location: New Delhi, India Madhusmita Sahu HealthBenefits email us here Visit us on social media: Instagram X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
30-06-2025
- Associated Press
IV Therapy Academy Announces Full-Tuition Scholarship for the Business Accelerator Program
IV Therapy Academy is Launching a New Annual Full-Tuition Scholarship for the Business Accelerator Training FL, UNITED STATES, June 30, 2025 / / -- IV Therapy Academy is thrilled to announce the launch of a new annual scholarship for the IV Therapy Business Accelerator Program. This scholarship offers an exceptional opportunity for licensed healthcare professionals to gain comprehensive training in IV hydration and nutritional therapy, clinical protocols, business strategies, and marketing. The IV Therapy Academy's Business Accelerator Program is designed to help practitioners integrate IV therapy into their practices effectively and safely. The scholarship aims to support healthcare professionals in expanding their skills and services by providing them with the tools and knowledge needed to offer IV hydration and nutrition in their clinics. Scholarship Details Award Frequency: Once a year Number of Scholarships: One full scholarship per year Eligibility: Open to NPs, CRNAs, PAs, Physicians, RNs, and any other licensed healthcare professionals with a strong interest in IV Therapy. How to Apply: Complete the Application Form: Provide your personal details, professional background, and your interest in IV hydration and nutritional therapy. Submit a 700-word Article: Write a 700-word article on any aspect of IV nutritional therapy that you are highly interested in, including APA citations. Application Timeline: Application Cycle: Apply between January 01 and May 31 (Awarded in July) Selection Process: The selection committee will review all applications and select the most qualified candidates based on their application form and submitted research paper. Applicants who demonstrate a strong commitment to patient care and a clear interest in IV hydration and nutritional therapy will be prioritized. Benefits of the Scholarship: Comprehensive Training: Gain in-depth knowledge from experts in IV therapy. Expand Your Services: Enhance your practice by offering IV therapy. Professional Growth: Develop specialized skills that set you apart in your field. To take advantage of this opportunity, prepare your application and submit it between January 01 and May 31. For questions or additional information, contact us at [email protected] or 407-315-1464. We look forward to your application! About IV Therapy Academy: IV Therapy Academy is dedicated to advancing the knowledge and skills of healthcare professionals in IV therapy. Our comprehensive training programs cover clinical protocols, business strategies, and operational essentials to help practitioners deliver effective and safe IV nutritional therapy. Through our IV Therapy Business Accelerator Program, we aim to equip healthcare professionals with the tools and knowledge needed to expand their services and enhance patient care. Jason Duprat, MBA, MSA, ARPN, CRNA Healthcare Boss Academy +1 407-315-1464 [email protected] Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
30-06-2025
- Associated Press
Vitalgen's Gene Therapy Drug VGN-R09b for Primary Parkinson's Disease Receives FDA Fast Track Designation
SHANGHAI, CHINA, June 30, 2025 / / -- Shanghai Vitalgen BioPharma Co., Ltd. ('Vitalgen') announced that its gene therapy drug, VGN-R09b, for the treatment of Primary Parkinson's Disease (PD), has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). VGN-R09b received IND approvals in China and the US in 2024, as a first-in-class recombinant adeno-associated virus (rAAV) gene therapy that targets two key pathways for the treatment of Parkinson's Disease (PD). The Phase I/II clinical trials have been ongoing in China since September, 2024, with all six patients dosed in the Phase I dose-escalation study. Safety data shows that the product is well-tolerated with no findings of VGN-R09b-related adverse events. Preliminary efficacy readouts show that VGN-R09b has a rapid onset of action, with significant gait improvements within two weeks post-treatment. The MDS-UPDRS Part III OFF scores decreased significantly after one month, with an average of 25-point improvements (approximately 50% improvements from the baseline) at six months. Overall, the Hoehn-Yahr (H-Y) scores progressively decreased, along with a reduction in oral medication dosages. The FTD indicates FDA's recognition of the clinical potential of VGN-R09b, marking an important milestone for Vitalgen's expansion into the chronic disease area, and it also represents a global breakthrough for a Chinese gene therapy company in the neurodegenerative field. Together with its FDA IND approval in July 2024, this FTD further validates VGN-R09b's global development potential and will provide expedited support for its future US clinical trials and regulatory filings. About Fast Track Designation (FTD) FTD is an FDA program designed to accelerate the development and approval of drugs that treat serious or life-threatening conditions and have the potential to address unmet medical needs. According to the performance report from the FDA's Center for Biologics Evaluation and Research (CBER), over 800 products have applied for FTD, with a success rate of approximately 68%. After receiving FTD, applicants are given the opportunity for frequent discussions with the FDA regarding their drug development plans, thereby increasing development efficiency. If the product meets certain criteria, it can qualify for accelerated approval, priority review, and rolling reviews, which can further accelerate development and market approval processes. About Parkinson's Disease (PD) Parkinson's Disease (PD) is the second most common neurodegenerative disease, with fast-growing incidences. It is projected that the global PD patient numbers will increase to more than 25 million by 2050. Current PD treatments are primarily small-molecule drugs for symptom relief. As the disease progresses, patients gradually lose response to oral medication, and significant motor complications persist despite fine-tuning the treatment regimens. There is currently no available treatment to delay disease progression or improve long-term outcomes. a: Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modeling study of Global Burden of Disease Study 2021. BMJ. 2025;388:e080952. doi:10.1136/bmj-2024-080952. About Vitalgen Vitalgen was founded in March 2020 as a cell and gene therapy (CGT) company based in Shanghai, China, dedicated to translating cutting-edge CGT technologies into clinically accessible treatments for patients worldwide. With proprietary intellectual property rights covering three core CGT platforms: ViVec® (AAV manufacturing platform), ViCas® (CRISPR gene-editing platform) and ViLNP® (Lipid nanoparticle delivery platform), Vitalgen has developed a diversified portfolio of innovative CGTs targeting CNS diseases, ophthalmic conditions, metabolic and hematologic disorders, and oncology, including multiple potential First-in-Class (FIC) products. Up-to-date, Vitalgen has received multiple rounds of investment from renowned venture funds and has established CGT R&D labs and operational centers in the Zhangjiang High-tech Park and a GMP commercial production facility in the Waigaoqiao Free Trade Zone, Shanghai, China. David Wu Vitalgen BioPharma email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
